FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110496778> ?p ?o ?g. }

• W2110496778 endingPage "2947" @default.
• W2110496778 startingPage "2940" @default.
• W2110496778 abstract "To evaluate the response rate, survival, and toxicity of mitoxantrone and cytarabine induction, high-dose cytarabine and etoposide intensification, and further consolidation/maintenance therapies, including bone marrow transplantation, in children with relapsed, refractory, or secondary acute myeloid leukemia (AML). To evaluate response to 2-chlorodeoxyadenosine (2-CDA) and etoposide (VP-16) in patients who did not respond to mitoxantrone and cytarabine.Patients with relapsed/refractory AML (n = 101) and secondary AML (n = 13) were entered.Mitoxantrone and cytarabine induction achieved a remission rate of 76% for relapsed/refractory patients and 77% for patients with secondary AML, with a 3% induction mortality rate. Cytarabine and etoposide intensification exceeded the acceptable toxic death rate of 10%. The response rate of 2-CDA/VP-16 was 8%. Two-year overall survival was estimated at 24% and was better than historical control data. Patients with secondary AML had similar outcomes to relapsed or refractory patients. Initial remission longer than 1 year was the most important prognostic factor for patients with primary AML (2-year survival rate, 75%), whereas for patients with primary AML, with less than 12 months of initial remission, survival was 13% and was similar to that of refractory patients (6%).Mitoxantrone and cytarabine induction is effective with reasonable toxicity in patients with relapsed/refractory or secondary AML. The cytarabine and etoposide intensification regimen should be abandoned because of toxicity. Patients with relapsed AML with initial remissions longer than 1 year have a relatively good prognosis." @default.
• W2110496778 created "2016-06-24" @default.
• W2110496778 creator A5016120310 @default.
• W2110496778 creator A5026088642 @default.
• W2110496778 creator A5052896867 @default.
• W2110496778 creator A5060210860 @default.
• W2110496778 creator A5065634167 @default.
• W2110496778 creator A5066861312 @default.
• W2110496778 creator A5067668831 @default.
• W2110496778 creator A5069315847 @default.
• W2110496778 creator A5070358005 @default.
• W2110496778 creator A5073322914 @default.
• W2110496778 creator A5082967648 @default.
• W2110496778 creator A5085057434 @default.
• W2110496778 date "2003-08-01" @default.
• W2110496778 modified "2023-10-02" @default.
• W2110496778 title "Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children’s Cancer Group Study 2951" @default.
• W2110496778 cites W1709114039 @default.
• W2110496778 cites W1905316660 @default.
• W2110496778 cites W1937764639 @default.
• W2110496778 cites W1972978214 @default.
• W2110496778 cites W2011489303 @default.
• W2110496778 cites W2020131910 @default.
• W2110496778 cites W2040336044 @default.
• W2110496778 cites W2062599504 @default.
• W2110496778 cites W2080006818 @default.
• W2110496778 cites W2096748176 @default.
• W2110496778 cites W2157633619 @default.
• W2110496778 cites W2159289068 @default.
• W2110496778 cites W2181860524 @default.
• W2110496778 cites W2187668060 @default.
• W2110496778 cites W2272218722 @default.
• W2110496778 cites W2327592010 @default.
• W2110496778 cites W2331485910 @default.
• W2110496778 cites W2339392195 @default.
• W2110496778 cites W2409426682 @default.
• W2110496778 cites W3147894994 @default.
• W2110496778 cites W4293241248 @default.
• W2110496778 cites W4474461 @default.
• W2110496778 doi "https://doi.org/10.1200/jco.2003.06.128" @default.
• W2110496778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12885813" @default.
• W2110496778 hasPublicationYear "2003" @default.
• W2110496778 type Work @default.
• W2110496778 sameAs 2110496778 @default.
• W2110496778 citedByCount "77" @default.
• W2110496778 countsByYear W21104967782012 @default.
• W2110496778 countsByYear W21104967782013 @default.
• W2110496778 countsByYear W21104967782014 @default.
• W2110496778 countsByYear W21104967782015 @default.
• W2110496778 countsByYear W21104967782016 @default.
• W2110496778 countsByYear W21104967782017 @default.
• W2110496778 countsByYear W21104967782018 @default.
• W2110496778 countsByYear W21104967782020 @default.
• W2110496778 countsByYear W21104967782021 @default.
• W2110496778 countsByYear W21104967782022 @default.
• W2110496778 countsByYear W21104967782023 @default.
• W2110496778 crossrefType "journal-article" @default.
• W2110496778 hasAuthorship W2110496778A5016120310 @default.
• W2110496778 hasAuthorship W2110496778A5026088642 @default.
• W2110496778 hasAuthorship W2110496778A5052896867 @default.
• W2110496778 hasAuthorship W2110496778A5060210860 @default.
• W2110496778 hasAuthorship W2110496778A5065634167 @default.
• W2110496778 hasAuthorship W2110496778A5066861312 @default.
• W2110496778 hasAuthorship W2110496778A5067668831 @default.
• W2110496778 hasAuthorship W2110496778A5069315847 @default.
• W2110496778 hasAuthorship W2110496778A5070358005 @default.
• W2110496778 hasAuthorship W2110496778A5073322914 @default.
• W2110496778 hasAuthorship W2110496778A5082967648 @default.
• W2110496778 hasAuthorship W2110496778A5085057434 @default.
• W2110496778 hasConcept C121332964 @default.
• W2110496778 hasConcept C126322002 @default.
• W2110496778 hasConcept C141071460 @default.
• W2110496778 hasConcept C142424586 @default.
• W2110496778 hasConcept C143998085 @default.
• W2110496778 hasConcept C2776611710 @default.
• W2110496778 hasConcept C2776694085 @default.
• W2110496778 hasConcept C2778041864 @default.
• W2110496778 hasConcept C2778119113 @default.
• W2110496778 hasConcept C2778461978 @default.
• W2110496778 hasConcept C2778729363 @default.
• W2110496778 hasConcept C2780923524 @default.
• W2110496778 hasConcept C71924100 @default.
• W2110496778 hasConcept C87355193 @default.
• W2110496778 hasConcept C90924648 @default.
• W2110496778 hasConceptScore W2110496778C121332964 @default.
• W2110496778 hasConceptScore W2110496778C126322002 @default.
• W2110496778 hasConceptScore W2110496778C141071460 @default.
• W2110496778 hasConceptScore W2110496778C142424586 @default.
• W2110496778 hasConceptScore W2110496778C143998085 @default.
• W2110496778 hasConceptScore W2110496778C2776611710 @default.
• W2110496778 hasConceptScore W2110496778C2776694085 @default.
• W2110496778 hasConceptScore W2110496778C2778041864 @default.
• W2110496778 hasConceptScore W2110496778C2778119113 @default.
• W2110496778 hasConceptScore W2110496778C2778461978 @default.
• W2110496778 hasConceptScore W2110496778C2778729363 @default.
• W2110496778 hasConceptScore W2110496778C2780923524 @default.
• W2110496778 hasConceptScore W2110496778C71924100 @default.
• W2110496778 hasConceptScore W2110496778C87355193 @default.

• next